Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Standard

Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA. / Met, Özcan; Svane, Inge Marie.

Synthetic Messenger RNA and Cell Metabolism Modulation. Bind 969 2013. s. 275-292 (Methods in Molecular Biology).

Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt

Harvard

Met, Ö & Svane, IM 2013, Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA. i Synthetic Messenger RNA and Cell Metabolism Modulation. bind 969, Methods in Molecular Biology, s. 275-292. https://doi.org/10.1007/978-1-62703-260-5_17

APA

Met, Ö., & Svane, I. M. (2013). Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA. I Synthetic Messenger RNA and Cell Metabolism Modulation (Bind 969, s. 275-292). Methods in Molecular Biology https://doi.org/10.1007/978-1-62703-260-5_17

Vancouver

Met Ö, Svane IM. Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA. I Synthetic Messenger RNA and Cell Metabolism Modulation. Bind 969. 2013. s. 275-292. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-62703-260-5_17

Author

Met, Özcan ; Svane, Inge Marie. / Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA. Synthetic Messenger RNA and Cell Metabolism Modulation. Bind 969 2013. s. 275-292 (Methods in Molecular Biology).

Bibtex

@inbook{610cae2d0f5041fb9fb779bbe41d812d,
title = "Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA",
abstract = "The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.",
author = "{\"O}zcan Met and Svane, {Inge Marie}",
year = "2013",
doi = "10.1007/978-1-62703-260-5_17",
language = "English",
isbn = "978-1-62703-259-9",
volume = "969",
series = "Methods in Molecular Biology",
publisher = "Humana Press",
pages = "275--292",
booktitle = "Synthetic Messenger RNA and Cell Metabolism Modulation",

}

RIS

TY - CHAP

T1 - Analysis of Survivin-Specific T Cells in Breast Cancer Patients Using Human DCs Engineered with Survivin mRNA

AU - Met, Özcan

AU - Svane, Inge Marie

PY - 2013

Y1 - 2013

N2 - The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

AB - The observation that dendritic cells (DCs) charged with tumor-associated antigens (TAAs) is a potent strategy to elicit protective immunity in tumor-bearings hosts has prompted extensive testing of DCs as cellular adjuvant in cancer vaccines. To improve the clinical development of DC-based cancer vaccines, it may be beneficial to analyze preexistent immunity against TAAs in cancer patients because it may be easier to expand a memory pool of T cells compared to generating new immunity. Recent research shows that engineering DCs to synthesize tumor epitopes endogenously by transfecting DCs with mRNA-encoding TAAs are particular effective in stimulating robust T-responses in vitro and in vivo. In this chapter, we describe the methodology to analyze for survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA.

U2 - 10.1007/978-1-62703-260-5_17

DO - 10.1007/978-1-62703-260-5_17

M3 - Book chapter

C2 - 23296940

SN - 978-1-62703-259-9

VL - 969

T3 - Methods in Molecular Biology

SP - 275

EP - 292

BT - Synthetic Messenger RNA and Cell Metabolism Modulation

ER -

ID: 245670540